Wednesday, Nov. 6, 2019
2 – 6:30 p.m.
With the approval of the first bispecific T-cell engager in 2018, and with many more such multi-targeted antibodies in clinical trials, there has been a resurgence of interest in these multi-functional platforms. Other related platforms, such as cytokine fusions and CAR T cell approaches, are also making their mark on the cancer treatment landscape. As these agents make their way into the clinic, however, many important scientific and clinical questions have been raised. During this half-day program, multi-targeted therapeutic platforms will be discussed by experts in the field, along with the opportunity for investigators to submit their own related work for consideration at this unique symposium.
The intended audience for this program includes, but is not limited to, basic, translational and clinical researchers; postdoctoral fellows; clinicians; and payers involved in cancer research from such affiliations as academia, industry and regulatory agencies.
- Alessandra Cesano, MD, PhD – NanoString, Inc.
- Edward Cha, MD, PhD – Genentech
- Leena Gandhi, MD, PhD – Eli Lilly
- Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
- Salil Patel, PhD – Bristol-Myers Squibb
- Eric Rubin, MD – Merck & Co., Inc.
Upon completion of this meeting, participants will be able to:
- Describe the different types of multi-targeted therapeutic platforms in preclinical and clinical studies.
- Explain the similarities and differences between multi-targeted therapies and other immunotherapies in clinical use, such as adoptive cell therapies.
- Understand the current state of clinical trials and approvals in cancer that employ multi-targeted therapeutic platforms.